|
gptkbp:instanceOf
|
gptkb:drug
biguanide
oral antidiabetic agent
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BX02
|
|
gptkbp:brand
|
GlucoNorm
Prandin
|
|
gptkbp:CASNumber
|
135062-02-1
|
|
gptkbp:category
|
antidiabetic agent
hypoglycemic agent
meglitinide analog
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:developedBy
|
gptkb:Novo_Nordisk
|
|
gptkbp:discoveredBy
|
gptkb:Novo_Nordisk
|
|
gptkbp:eliminationHalfLife
|
1 hour
|
|
gptkbp:hasInChIKey
|
X2VC9N5NQK2D1E-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C27H36N2O4
|
|
gptkbp:hasSMILES
|
CC(C)CC1=CC=CC=C1N2CCCC2C(=O)NCC3=CC(=C(C=C3)OCC)C(=O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
repaglinide
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:rifampin
gptkb:clopidogrel
gptkb:gemfibrozil
gptkb:ketoconazole
|
|
gptkbp:KEGGID
|
D08415
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1997
|
|
gptkbp:mechanismOfAction
|
stimulates insulin secretion from pancreatic beta cells
|
|
gptkbp:MeSH_ID
|
D000068162
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
452.6 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
>98%
|
|
gptkbp:PubChem_CID
|
CHEMBL1091
59385
65981
DB00912
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
weight gain
gastrointestinal upset
|
|
gptkbp:synonym
|
(-)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid
|
|
gptkbp:UNII
|
7183483U51
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:CYP2C8
gptkb:biguanide
|
|
gptkbp:bfsLayer
|
6
|